Incyte (STU:ICY) Other Net Income (Loss) : €-0 Mil (TTM As of Sep. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Incyte Other Net Income (Loss)?

Incyte's Other Net Income (Loss) for the three months ended in Sep. 2024 was €0 Mil. Its Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 was €-0 Mil.

Incyte's quarterly Other Net Income (Loss) declined from Mar. 2024 (€0 Mil) to Jun. 2024 (€0 Mil) but then stayed the same from Jun. 2024 (€0 Mil) to Sep. 2024 (€0 Mil).

Incyte's annual Other Net Income (Loss) declined from Dec. 2021 (€0 Mil) to Dec. 2022 (€-0 Mil) but then increased from Dec. 2022 (€-0 Mil) to Dec. 2023 (€0 Mil).

Incyte Other Net Income (Loss) Historical Data

The historical data trend for Incyte's Other Net Income (Loss) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Other Net Income (Loss) Chart

Incyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Other Net Income (Loss)

Get a 7-Day Free Trial

Incyte Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Other Net Income (Loss)	Get a 7-Day Free Trial															-	-	-	-	-

Incyte Other Net Income (Loss) Calculation

Different companies can and do choose to report each of income statement items separately. Yet, there are a variety of items which are simply too numerous to list. Therefore GuruFocus uses a standardized financial statement format for all companies. Other Net Income (Loss) may include but is not limited to items such as net income (loss) from discontinuing operations, extraordinary, earnings from equity interest net of tax, etc. After-tax income and Other Net Income (Loss) together constitute Net Income Including Noncontrolling Interests.

Other Net Income (Loss) for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0 Mil.

Incyte Other Net Income (Loss) Related Terms

Thank you for viewing the detailed overview of Incyte's Other Net Income (Loss) provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (STU:ICY) » Definitions » Other Net Income (Loss)

Comparable Companies

Traded in Other Exchanges

INCY:USA INCY:Mexico 1INCY:Italy 0J9P:UK ICY:Germany I1NC34:Brazil

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines